Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches

被引:56
|
作者
Mannix, Sally [1 ]
Skalicky, Anne [1 ]
Buse, Dawn C. [2 ,3 ]
Desai, Pooja [4 ]
Sapra, Sandhya [4 ]
Ortmeier, Brian [4 ]
Widnell, Katherine [4 ]
Hareendran, Asha [1 ,5 ]
机构
[1] Evidera, Bethesda, MD 20814 USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] Evidera, London, England
关键词
Migraine; Concept elicitation; Development; Functioning; Instrument; PRO; Headache; COA; PATIENT-REPORTED OUTCOMES; AMERICAN MIGRAINE; UNITED-STATES; CONTENT VALIDITY; PREVALENCE; BURDEN; QUESTIONNAIRE; INSTRUMENTS; EXPERIENCES; VALIDATION;
D O I
10.1186/s12955-016-0542-3
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Migraine is characterized by headache with symptoms such as intense pain, nausea, vomiting, photophobia, and phonophobia that significantly impact individuals' lives. The objective of this study was to develop a strategy to measure outcomes from the patients' perspectives for use in evaluating preventive treatments for migraine. Methods: This study used a multi-stage process. The first stage included concept identification research through literature review, patient-reported outcome (PRO) instrument content review, and clinician interviews, and resulted in a list of concepts relevant to understand the migraine experience. These results informed the design of the subsequent concept elicitation stage that involved qualitative interviews of adults with migraine to understand their experiences. Information from these two stages was used to develop a conceptual disease model (CDM) of the migraine experience. This CDM was used to identify concepts of interest (COI) to evaluate patient-relevant outcomes for assessing treatment benefit of migraine prophylactics. In the final stage, existing PRO instruments were reviewed to assess coverage of concepts related to the selected COI. Results: Nine articles from 563 screened abstracts underwent full review to identify migraine-relevant concepts. This concept identification and subsequent concept elicitation interviews (N = 32; 21 episodic migraine; 11 chronic migraine) indicated that people with migraine experience difficulties during and between migraine attacks with considerable day-to-day variability in the impact on movement, ability to perform every day and social activities, and emotion. The CDM organized concepts as proximal to and more distal from disease-defining migraine symptoms, and was used to identify impact on physical function as the key COI. The item level review of PRO instruments revealed that none of the existing PRO instruments were suitable to collect data on impact of migraine on physical functioning, to evaluate treatment benefit. Conclusions: The impact of migraine includes impairments in functioning during and between migraine attacks that vary considerably on a daily basis. There is a need for novel PRO instruments that reflect patients' migraine experience to assess treatment benefit of migraine prophylactics. These instruments must evaluate the concepts identified and be able to capture the variability of patients' experience.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches
    Sally Mannix
    Anne Skalicky
    Dawn C. Buse
    Pooja Desai
    Sandhya Sapra
    Brian Ortmeier
    Katherine Widnell
    Asha Hareendran
    [J]. Health and Quality of Life Outcomes, 14
  • [2] Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ)
    Hareendran, Asha
    Skalicky, Anne
    Mannix, Sally
    Lavoie, Sara
    Desai, Pooja
    Bayliss, Martha
    Thach, Andrew V.
    Mikol, Daniel D.
    Buse, Dawn C.
    [J]. HEADACHE, 2018, 58 (10): : 1612 - 1628
  • [3] New and Emerging Treatments for the Acute and Preventive Therapy of Migraine and Other Headaches
    Schwedt, Todd J.
    [J]. HEADACHE, 2019, 59 : 1 - 2
  • [4] RimabotulinumtoxinB for preventive treatment of migraine headaches
    Grogan, P. M.
    Alvarez, M. V.
    [J]. TOXICON, 2013, 68 : 74 - 75
  • [5] The use of migraine preventive medications among patients with and without migraine headaches
    Lafata, J. E.
    Tunceli, O.
    Cerghet, M.
    Sharma, K. P.
    Lipton, R. B.
    [J]. CEPHALALGIA, 2010, 30 (01) : 97 - 104
  • [6] Work impact of migraine headaches
    Stewart, Walter F.
    Wood, G. Craig
    Razzaghi, Hanieh
    Reed, Michael L.
    Lipton, Richard B.
    [J]. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2008, 50 (07) : 736 - 745
  • [7] General practitioners with migraine: perceptions, treatment and impact of migraine headaches
    Ducros, A.
    Romatet, S.
    Saint Marc, T.
    Allaf, B.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S73 - S73
  • [8] Migraine headaches
    Kernich, Catherine A.
    [J]. NEUROLOGIST, 2008, 14 (05) : 337 - 338
  • [9] MIGRAINE HEADACHES
    OPPENHEIM, R
    FABARA, J
    [J]. EAR NOSE & THROAT JOURNAL, 1982, 61 (05): : 270 - 272
  • [10] Migraine headaches
    Semenov, Irene A.
    [J]. DM DISEASE-A-MONTH, 2015, 61 (06): : 218 - 222